Saroja Pharma Indus Ind L Stock Price Today (NSE: SAROJA)
Fundamental Score
Saroja Pharma Indus Ind L Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Saroja Pharma Indus Ind L share price today is ₹28.00, up +0.00% on NSE/BSE as of 30 March 2026. Saroja Pharma Indus Ind L (SAROJA) is a Small-cap company in the Specialty Chemicals sector with a market capitalisation of ₹16.89 (Cr). The 52-week high for SAROJA share price is ₹60.00 and the 52-week low is ₹28.15. At a P/E ratio of 13.30x, SAROJA is currently trading below its industry average P/E of 29.20x. The company has a Return on Equity (ROE) of 6.79% and a debt-to-equity ratio of 0.65.
Saroja Pharma Indus Ind L Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Saroja Pharma Indus Ind L Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Saroja Pharma Indus Ind L Share Price: A Conservative Value Investor's Perspective
In the specialty chemicals sector, customized solutions and efficient manufacturing are key. Smaller players often thrive by catering to niche markets abandoned by larger corporations, offering flexibility and bespoke formulations. This analysis examines the Saroja Pharma Indus Ind L share price from a conservative value investing perspective, prioritizing capital safety and long-term sustainability. We are looking for companies that demonstrate financial prudence and consistent profitability.
Currently trading at ₹36.04999923706055, Saroja Pharma Indus Ind L boasts a PE ratio of 13.3. This appears relatively attractive compared to some broader market averages. However, a low PE alone does not guarantee value. Our scrutiny extends to the quality of earnings and the underlying business's capacity to generate consistent returns. Another point of concern is that peers such as
Amal may have different corporate governance practices, and investors should look into management quality.A critical metric for our analysis is the Return on Capital Employed (ROCE) which currently stands at 12.57%. A sustainable ROCE above the company's cost of capital is essential for building a durable economic moat. While 12.57% is reasonable, we would need to assess its consistency over several years and compare it against sector averages (including competitors like Bhatia Colour and Deep Polymers) to determine its true competitive strength. A higher ROCE implies the company is efficiently deploying capital and generating more profit per rupee invested, making it harder for competitors to erode its market share.
Furthermore, while the current valuation, based on the PE ratio, appears reasonable, a deep dive into the balance sheet is vital. Conservative investors prioritize strong balance sheets with minimal debt and healthy cash flows. We need to understand the company's debt levels, cash conversion cycle, and working capital management to gauge its financial resilience. This observational analysis is part of a comprehensive 80-parameter fundamental audit, rigorously verified by Sweta Mishra, to ensure objectivity and thoroughness in our assessment.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Saroja Pharma Indus Ind L Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SAROJA across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Attractive Valuation (P/E: 13.30 vs Industry: 29.20)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (67.65%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (106.28%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Balanced Promoter Holding (73.02%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (6.79%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Margin Pressure Concerns (4.84%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Weak Interest Coverage (2.42x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-11.77 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Saroja Pharma Indus Ind L Financial Statements
Comprehensive financial data for Saroja Pharma Indus Ind L including income statement, balance sheet and cash flow
About SAROJA (Saroja Pharma Indus Ind L)
Saroja Pharma Indus Ind L (SAROJA) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Specialty Chemicals sector w...ith a current market capitalisation of ₹16.89 (Cr). Saroja Pharma Indus Ind L has delivered a Return on Equity (ROE) of 6.79% and a ROCE of 12.57%. The debt-to-equity ratio stands at 0.65, reflecting the company's capital structure. Investors tracking SAROJA share price can monitor key metrics including P/E ratio, promoter holding of 73.02%, and quarterly earnings growth.
Company Details
SAROJA Share Price: Frequently Asked Questions
What is the current share price of Saroja Pharma Indus Ind L (SAROJA)?
As of 30 Mar 2026, 12:02 pm IST, Saroja Pharma Indus Ind L share price is ₹28.00. The SAROJA stock has a market capitalisation of ₹16.89 (Cr) on NSE/BSE.
Is SAROJA share price Overvalued or Undervalued?
SAROJA share price is currently trading at a P/E ratio of 13.30x, compared to the industry average of 29.20x. Based on this relative valuation, the Saroja Pharma Indus Ind L stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of SAROJA share price?
The 52-week high of SAROJA share price is ₹60.00 and the 52-week low is ₹28.15. These values are updated daily from NSE/BSE price data.
What factors affect the Saroja Pharma Indus Ind L share price?
Key factors influencing SAROJA share price include quarterly earnings growth (Sales Growth: 106.28%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Saroja Pharma Indus Ind L a good stock for long-term investment?
Saroja Pharma Indus Ind L shows a 5-year Profit Growth of N/A% and an ROE of 6.79%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.65 before investing in SAROJA shares.
How does Saroja Pharma Indus Ind L compare with its industry peers?
Saroja Pharma Indus Ind L competes with major peers in the Specialty Chemicals. Investors should compare SAROJA share price P/E of 13.30x and ROE of 6.79% against the industry averages to determine competitive standing.
What is the P/E ratio of SAROJA and what does it mean?
SAROJA share price has a P/E ratio of 13.30x compared to the industry average of 29.20x. Investors pay ₹13 for every ₹1 of annual earnings.
How is SAROJA performing according to Bull Run's analysis?
SAROJA has a Bull Run fundamental score of 41.7/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SAROJA belong to?
SAROJA operates in the Specialty Chemicals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Saroja Pharma Indus Ind L share price.
What is Return on Equity (ROE) and why is it important for SAROJA?
SAROJA has an ROE of 6.79%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Saroja Pharma Indus Ind L generates profits from shareholders capital.
How is SAROJA debt-to-equity ratio and what does it indicate?
SAROJA has a debt-to-equity ratio of 0.65, which indicates moderate leverage that should be monitored.
What is SAROJA dividend yield and is it a good dividend stock?
SAROJA offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Saroja Pharma Indus Ind L shares.
How has SAROJA share price grown over the past 5 years?
SAROJA has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in SAROJA and why does it matter?
Promoters hold 73.02% of SAROJA shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Saroja Pharma Indus Ind L.
What is SAROJA market capitalisation category?
SAROJA has a market capitalisation of ₹17 crores, placing it in the Small-cap category.
How volatile is SAROJA stock?
SAROJA has a beta of N/A. A beta > 1 suggests the Saroja Pharma Indus Ind L stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SAROJA operating profit margin trend?
SAROJA has a 5-year average Operating Profit Margin (OPM) of 4.84%, indicating the company's operational efficiency.
How is SAROJA quarterly performance?
Recent quarterly performance shows Saroja Pharma Indus Ind L YoY Sales Growth of 106.28% and YoY Profit Growth of 67.65%.
What is the institutional holding pattern in SAROJA?
SAROJA has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Saroja Pharma Indus Ind L stock.